Ectodomain Mutations Alter the Proteolysis of the Amyloid-β Precursor Protein (APP) by Mitsumori, Michael S.
Dominican Scholar 
Graduate Master's Theses, Capstones, 
and Culminating Projects Student Scholarship 
5-2015 
Ectodomain Mutations Alter the Proteolysis of the Amyloid-β 
Precursor Protein (APP) 
Michael S. Mitsumori 
Dominican University of California 
https://doi.org/10.33015/dominican.edu/2015.bio.06 
Survey: Let us know how this paper benefits you. 
Recommended Citation 
Mitsumori, Michael S., "Ectodomain Mutations Alter the Proteolysis of the Amyloid-β 
Precursor Protein (APP)" (2015). Graduate Master's Theses, Capstones, and Culminating 
Projects. 179. 
https://doi.org/10.33015/dominican.edu/2015.bio.06 
This Master's Thesis is brought to you for free and open access by the Student Scholarship at 
Dominican Scholar. It has been accepted for inclusion in Graduate Master's Theses, Capstones, and 
Culminating Projects by an authorized administrator of Dominican Scholar. For more information, 
please contact michael.pujals@dominican.edu. 
1 
 
Ectodomain Mutations Alter the Proteolysis of the 
Amyloid-β Precursor Protein (APP) 
 
A thesis submitted to the faculty of 
Dominican University of California 
And the Buck Institute for Research on Aging 
 



























Certification of Approval 
I certify that I have read Ectodomain Mutations Alter the Proteolysis of the Amyloidβ Precursor 
Protein by Michael Mitsumori, and I approved this thesis to be submitted in partial fulfillment 
of the requirements for the degree: Master of Sciences in Biology at Dominican University of 
California and the Buck Institute for Research on Aging. 
        
            
Varghese John 
Graduate Research Advisor 
Ph. D. 
 
     
Clare Libeu 
Graduate Research Advisor 
Ph. D. 
 









Table of Contents 
Copyright           2 
Certification of Approval         3 
Table of Contents          4 
Abbreviations           7 
Abstract           8 
Acknowledgements          9 
Specific Aims           10 
Introduction           11 
I. Impact 
II. Symptoms and Treatment 
III. Late-Onset Alzheimer’s Disease (LOAD) and Early-Onset Alzheimer’s Disease 
(EOAD) 
IV. Amyloid Plaques and Neurofibrillary Tangles 
V. APP Proteolysis- Formation of trophic and Anti-trophic Peptides 
VI. APP Structure 
VII. Known APP Mutations 
VIII. APP Ectodomain Mutations 
5 
 
Research Design and Methods        21 
I. Computer Modeling 
II. Mutagenesis 
III. RGB Transformation 
IV. Expression 
V. Purification 
VI. Chinese Hamster Ovary (CHO) Cell Culture 
VII. Human Embryonic Kidney (HEK) Cell Culture  
VIII. Transfection 
IX. Lysis 
X. Western Blot 
XI. LacZ Assay 
XII. BACE and ADAM10 AlphaLISA Cleavage Assay 
Results            30 
I.  Computer Modeling 
II. Protein Purification 
III. CHO Cell 
IV. HEK Cell 
Discussion           40 
Conclusion           45 
6 
 














AD= Alzheimer’s disease 
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APP= Amyloid-β Precursor Protein 
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Alzheimer’s disease (AD) is the most common form of dementia, affecting over 5 million 
Americans.   In AD patients there is a buildup of amyloid plaque in the brain, which contributes 
to AD symptoms.  The main component of plaques is Amyloid-β (Aβ), a 40-42 length peptide 
formed from Amyloid-β Precursor Protein (APP) proteolysis.  APP proteolysis can result in either 
anti-trophic or trophic peptides.  Several APP polymorphisms exist that cause or protect against 
AD by altering APP proteolysis.  Recently, more polymorphisms in the APP ectodomain have 
been discovered in patients with late onset AD (LOAD).  The proteolysis of APP may be affected 
by these mutations, and we aim to determine their effect by measuring the levels of trophic 
and anti-trophic peptides produced in protein assays, Chinese Hamster Ovary (CHO) cells, and 
Human Embryonic Kidney (HEK) cells.  We discovered that the N585Y APP polymorphism is 
likely to cause onset of LOAD through increased levels of anti-trophic peptides and decreased 
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Alternative APP proteolysis results in the generation of small peptides that produce 
either an anti-trophic or trophic effect.  Peptides responsible for the anti-trophic effect (Aβ, 
sAPPβ, APPneo, Jcasp, and C31) play a role in the onset of AD, while trophic peptides (sAPPα, 
αCTF, p3, and AICD) protect against AD.  Mutations to the APP ectodomain may affect its 
proteolysis by BACE and ADAM10, resulting in altered formation of anti-trophic and trophic 
peptides.  Our proposed study aims to determine if this phenomenon occurs in vitro.  We will 
investigate by conducting the following specific aims: 
(1)  Creating APP ectodomain mutants. 
(2)  Purifying mutant protein and conducting cleavage assays to measure the effect of 
mutations on proteolytic cleavage. 
(3) Expressing mutants in Chinese Hamster Ovary Cells (CHO) and Human Embryonic 
Kidney Cells (HEK) and detecting cleavage products to determine the in vitro effect 







I.  Impact 
Alzheimer’s disease (AD) has an enormous effect on communities, families, the health 
care system, and the individuals diagnosed with the disease.  In 2014, an estimated 5.2 million 
Americans had AD, of which 5 million were over the age of 65 (1).  One in nine people over the 
age of 65 has AD, and one-third of people older than 85 have AD (2).  Every 67 seconds, 
someone develops a new case (2).  The number of deaths from AD was 84,767 people in 2013, 
making AD the 6th leading cause of death in the United States (3).  Total cost of AD care in 2015 
was estimated at $226 billion, with Medicare and Medicaid covering around $153 billion.  Out-
of-pocket spending will account for $44 billion (2). 
The number of AD patients is expected to increase in the future as the segment of the 
US population over the age of 65 increases (4).  In 2010, thirteen percent of the population was 
over the age of 65 (5).  Estimates show that by 2030, twenty percent of the population will be 
over the age of 65 (5).  By 2025, the number of AD patients will have increased to 7.1 million 
(1).  By mid-century, a projected 13.8 million people will have AD (1), with a new case arising 
every 33 seconds (2). 
II. Symptoms and Treatment   
 AD symptoms vary per person, but commonly begin with a gradual decrease in the 
ability to remember new information.  As AD progresses, affected individuals experience 
further difficulties such as memory loss that disrupts daily life, challenges in planning or solving 
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problems, difficulty in completing familiar tasks, confusion with time or place, trouble 
understanding visual images and spatial relationships, new problems with words in speaking or 
writing, misplacing things and losing the ability to retrace steps, decreased or poor judgment, 
withdrawal from work or social activities, and/or changes in mood and personality (primarily 
apathy and depression).  In the late stages of the disease, people require assistance to perform 
basic activities (bathing, eating, dressing, using the bathroom, etc.), lose the ability to 
communicate, fail to recognize loved ones, and become bed-bound and reliant upon around-
the-clock care. (2) 
 Although there is no cure for AD, pharmacologic and non-pharmacologic therapies are 
employed with varied results to treat symptoms.  There are dozens of drugs and therapies 
being researched throughout the world (2).  Currently, six drugs have been approved by the 
U.S. Food and Drug Administration that temporarily improve AD symptoms by increasing the 
amount of neurotransmitters in the brain (6).  The effectiveness of these drugs has varied per 
person.  Non-pharmacologic treatments have largely been ineffective, with the exception of 
cognitive stimulation (7).  More research is required to identify effective pharmacologic or non-
pharmacologic therapies or cures. 
III. Late-Onset Alzheimer’s Disease (LOAD) and Early-Onset Alzheimer’s Disease (EOAD) 
 AD can be divided into two types: Early-Onset Alzheimer’s Disease (EOAD) and Late-
Onset Alzheimer’s Disease (LOAD) (figure 1).  EOAD patients consist of 5-10% of the total AD 
population and are diagnosed with AD before reaching 65 years of age (8, 9).  Fifty percent of 
EOAD cases are familial Alzheimer’s disease (FAD), which is caused by mutations in APP, PSEN, 
 
or Tau (10, 11).  LOAD patients consist of about 
diagnosed with AD after turning 65 years of age
environmental factors, but may involve
ectodomain mutations. 
IV. Amyloid Plaques and Neurofibrillary Tangles
The pathological hallmarks of AD include the
space of the brain and the intercellular buildup of neurofibrillary tangles
Figure 1.  EOAD and LOAD.  AD can be divided into two types: Early
(EOAD) and Late-Onset Alzheimer’s Disease (LOAD).  The majority of AD patients have LOAD, 
which occurs after age 65 and is caused by environmental factors or genetic ri
a small portion of AD patients have EOAD, w
mutations to APP, PSEN, and Tau.
95% of the total AD population and are 
 (8, 9, 11).  LOAD is primarily caused by 
 genetic risk factors (8) such as the APOE4 
 
 buildup of amyloid plaque in 
 (12) (fi
-Onset Alzheimer’s Disease 
hich occurs before age 65 and is caused by 
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extracellular 
gure 2).  
sk factors.  Only 
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Amyloid plaques are composed of the Amyloid-β peptide (Aβ), a 40-42 length peptide formed 
from the proteolytic cleavage of the Amyloid-β Precursor Protein (APP) (13).  Aβ plays an 
important role in the development of AD, and studies have shown that its properties include a 
detergent-like effect, metal binding (14, 15), activation of cell death pathways (16, 17), 
interaction with extracellular receptors (18, 19, 20), and generation of reactive oxygen species 
(21). 
In AD, there is also a buildup of neurofibrillary tangles that are composed of 
hyperphosphorylated Tau proteins.  Tau proteins are a part of the microtubule-associated 
proteins family, and assist with the formation and stabilization of microtubules (22).  Tau 
protein ability to bind microtubules is dependent on its phosphorylation state, which is 
regulated by kinases and phosphatases (23).  When hyperphosphorylated under certain 






V.  APP Proteolysis- Formation of Trophic and Anti-Trophic Peptides 
 The formation of the Aβ peptide found in amyloid plaques occurs during the proteolysis 
of APP.  APP proteolysis is an event that occurs when APP, a type I transmembrane protein, is 
cleaved by several proteolytic enzymes called secretases to produce either trophic or anti-
trophic peptides (25, 26) (figure 3).  Trophic peptides are amino acid chains that affect the cell 
by stimulating cell growth, differentiation, and survival (26).  Anti-trophic peptides produce the 
Figure 2.  The hallmarks of AD: amyloid plaques and neurofibrillary tangles.  Amyloid plaques 
are composed of Aβ peptides formed through proteolytic cleavage of APP.  Neurofibrillary 
tangles are composed of hyperphosphorylated Tau proteins, which assist with microtubule 
formation and stabilization. 
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opposite effect, inhibiting cell growth and differentiation, and activating cell death pathways 
(26).  During anti-trophic peptide formation, β secretase (BACE) and γ-secretase cleave APP at 
the β and γ-sites, respectively, resulting in the products Aβ and sAPPβ (25, 26, 27).  Further 
intracellular proteolytic processing produces  Jcasp and C31.  These peptides are involved in the 
anti-trophic effects that lead to AD (26).  Alternatively, APP processing can produce trophic 
peptides (26).  APP is cleaved by α secretase (ADAM10) at the α-cleavage site, resulting in the 
formation of sAPPα and αCTF, two trophic peptides that protect against AD (26). 
 
 
Figure 3.  Alternative APP proteolysis.   APP cleavage produces either trophic or anti-trophic 
peptides.  When initial cleavage occurs at the β site, anti-trophic peptides are produced.  
However, if initial cleavage occurs at the α site, trophic peptides are produced. 
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Several recent studies have demonstrated that alternative APP proteolysis can be 
altered through interactions with biological molecules other than the proteolytic enzymes (28).  
In the absence of Aβ, APP exists as a homodimer.  Dimeric Aβ induces monomerization of APP, 
while Aβ oligomers stabilize the APP homodimer (29).  APP dimerization can influence APP 
proteolysis.  Small molecules such as disulfiram and sulfiram, which inhibit APP dimerization, 
enhance the production of sAPPα (30).  A group led by Dr. Selkoe measured sAPPα and sAPPβ 
levels to determine the activity of proteolytic enzymes in the presence of various known APP 
ligands (31).  Using sAPPα and sAPPβ levels to determine proteolytic activity is a useful method, 
and we will employ this method in determining the effect of APP ectodomain mutations on APP 
proteolysis.  The Bredesen laboratory and other groups have shown that an important 
interaction occurs between sAPPα and BACE, and the association of these two molecules 
inhibits Aβ production (32, 33).  Furthermore, decreasing sAPPα levels results in an increase of 
Aβ (32).  APP ectodomain mutations may affect the ability of APP to interact with these 
biological molecules.  Study of LOAD mutants may reveal altered interactions that result in 
altered levels of APP cleavage products and increased or decreased risk of AD. 
VI. APP Structure 
The APP ectodomain consists of various regions with unique functions (figure 4).  The E1 
region contains the Growth Factor-like Domain (GFLD) and the Copper Binding Domain (CuBD) 
and is nearest the N terminus (34).  The E2 region contains the RERMS sequence and is capable 
of binding other proteins (35).  The acidic region, composed primarily of acidic residues, 
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connects the E1 and E2 regions (34).  Acidic region function is unknown and no other human 
protein contains a similar region (36).  
 
 
VII. Known APP Mutations 
 Several polymorphisms have been found to have an effect on APP proteolysis.  The 
Icelandic APP polymorphism was found to be protective against AD.  It is located near the β-
cleavage site and reduces the amount of anti-trophic peptides produced (39).  It is possible that 
more APP polymorphisms exist that can also protect against AD.   
Figure 4.  APP structure.  Shows the various regions and domains of APP.  The E1 region is 
located nearest the N terminus and consists of the Growth Factor-like Domain (GFLD) and 
the Copper Binding Domain (CuBD).  The E2 region contains the RERMS sequence and the 
Central APP Domain (CAPPD) and is capable of interaction with other proteins.  The acidic 
region is composed primarily from acidic residues, connects the E1 and E2 regions, and has 






Acidic AICD JMK GFLD CuBD RERMS CAPPD 
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Two other polymorphisms shift APP proteolysis towards the formation of anti-trophic 
peptides and have been linked with EOAD.  The Swedish APP mutation is located near the β-
cleavage site and increases the amount of Aβ produced (37).  The Indiana APP mutation is 
located within the APP transmembrane domain near the γ-cleavage site (38).  It is possible that 
more APP polymorphisms exist that shift APP proteolysis towards the formation of anti-trophic 
peptides that cause or increase risk of AD.   In this study, we will investigate several candidate 
polymorphisms that are likely to alter APP proteolysis. 
VIII. APP Ectodomain Mutations 
A recent study has discovered several APP ectodomain variants found in late onset AD 
(LOAD) patients (40) (figure 5).  It is unknown how these variants contribute to AD.  In order to 
shed light on their mechanism of action, we chose the N585Y and E191G for detailed study.  
The E426K and D243N are other candidates for this study.  The N585Y variant is located near 
the β-cleavage site.  The E426K variant is located in the E2 region and the E191G and D243N 
variants are located in the APP acidic region, which has unknown function.  Studies of one of 
these mutants may provide insights towards acidic region function and any effects on APP 
proteolysis.  The table below (figure 5 a.) shows the various mutants, their location within APP, 
and their previously observed effect.  The H147N variant is not associated with LOAD, is located 










These APP ectodomain mutations can have a wide range of effects.  Mutations may 
affect APP interaction with physiological binding partners, including the proteolytic enzymes 
responsible for APP proteolysis.  Altered interaction with t
secreted and intracellular levels of APP cleavage products in CHO cells.  Mutations may also 
Figure 5 a.  Table of the known APP ectodomain mutations, their location, and observed 
effect.  Mutations in bold are the ones involved in this study.








CuBD ↑ intracellular sAPP
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cause conformational changes to cleavage sites, affecting proteolytic activity.  These 
conformational changes would also alter cleavage product levels.  Because cleavage product 
levels are an indication of altered interaction with proteolytic enzymes and can affect the onset 
of AD, we aim to measure the cleavage products of APP ectodomain mutations.  The mutations 
that we have focused on in this study are the N585Y, the E191G, and the H147N.  Because the 
N585Y is located close to the β-cleavage site, we believe that is the most likely of the mutations 
to alter cleavage product levels.  The E191G mutation is located within the acidic region of APP, 
and we believe that studying this mutant may provide insights toward the function of that 
region.  The H147N has been the focus of other studies (9), and we aim to use it as a positive 
control in our experiments. 
Research Design and Methods 
I. Computer Modeling 
To aid in predicting the effect of APP ectodomain mutations on APP cleavage, mutations 
were mapped on a model of APP.  The model created by Dr. Clare Peters-Libeu represents a 
possible structure of APP based on computer modeling data derived from small angle x-ray 
scattering (SAXS) data (33).  The program Chimera was used to mark the location of the 
mutants studied. 
II.  Mutagenesis 
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To create mutants, pDEST-HisMBP plasmid containing wild type APP695 were used for 
expression in Rosetta-gami B (RGB) cells (plasmid shown below).   For transfection in CHO cells, 
pcDNA3 plasmids containing mutant or wild-type APP695 were used.  Mutations were 
introduced using the Quikchange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, 
Santa Clara, CA) using primers designed with the primer design tool at 
http://www.genomics.agilent.com/primerDesignProgram.jsp?&_requestid=1597773. 
Mutagenesis reactions were prepared by adding 5 µL of 10x reaction buffer, 10 ng of pDEST-
HisMBP plasmid containing wild-type APP695, 125 ng of primer #1, 125 ng of primer #2, 1 µL of 
dNTP mix, 3 µL of QuikSolution, and ddH2O to a final volume of 50 µL to a PCR tube.  One µL of 
pfuUltra HF DNA Polymerase was added, and the PCR reaction was cycled according to the 
QuikChange II XL handbook parameters (shown below). 
 
 Following PCR cycling, 1 µL of Dpn I restriction enzyme was added to each reaction to 
digest nonmutated DNA, and reactions were incubated at 37oC for 1 hour.  DPN I digestion was 
followed by an XL10-Gold transformation to increase plasmid yield.  XL10-Gold ultracompetent 
cells stored at -80oC were first thawed on ice.  Forty-five µL of cells were transferred to 
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prechilled 14 mL Falcon polypropylene round-bottom tubes and 2 µL of β-ME was added.  The 
cells were incubated on ice for 10 minutes, swirling every 2 minutes.  Two µL of Dpn I-treated 
plasmid was then added to the cells.  Following a 30 minute incubation on ice, the cells were 
heat shocked in a 42oC water bath for 30 seconds.  The cells were then incubated on ice for 2 
minutes and 0.5 mL of SOC, preheated to 42oC, was added.  Reaction mixtures were then 
incubated at 37oC for 1 hour with shaking at 250 RPM.  Cells were plated onto NIM plates with 
carbenicillan and incubated at 37oC overnight.  A Qiagen miniprep kit (Qiagen, Hilden, 
Germany) was used to isolate mutated DNA from the plated cells. 
III. RGB Transformation 
 Once mutant APP695 pDEST-HisMBP plasmids were created, they were transformed 
into RGB cells for protein expression.  RGB is a strain of E. coli that is designed to enhance the 
expression of eukaryotic proteins through its deficiency in lon and ompT proteases (prevents 
protein degradation), mutations to thioredoxin reductase (trxB) and glutathione reductase (gor) 
(enhances disulfide bond formation in cytoplasm), and addition of specific tRNAs that are rarely 
used in E. coli.  RGB cells stored at -80oC were first thawed on ice.  Twenty µL was then added 
to chilled 1.5 mL microcentrifuge tubes and 2 µL of pDEST-HisMBP plasmid containing wild-type 
or mutant APP695 was added.  Tubes were placed on ice for 5 minutes, heat shocked in a 42oC 
water bath for 30 seconds, and then placed on ice for 2 minutes.  Eighty µL of SOC media was 
added, and tubes were incubated in a shaker set to 250 RPM for 1 hour at 37oC.  Finally, RGB 
cells were plated onto NIM plates with carbenicillan and chloramphenicol and incubated at 




Mutant and wild-type APP695 protein was expressed by inoculating 30 mL of NIM media 
with RGB cells containing mutant APP pDest-HisMBP plasmids and shaking overnight at 280 
RPM at 30oC.  Using 3 mL of this overnight culture, 1L of LB was inoculated and grown while 
shaking at 280 RPM at 30oC until OD 600 nm was close to 0.5-0.6.   Expression was induced by 
adding 0.1 mg/mL IPTG and shaking for 10-12 hours at 280 RPM at 24oC.  Finally, cultures were 
moved to 4oC for 10-24 hours. 
V. Purification 
Mutant protein was purified from RGB cells following transformation and expression 
steps.  Mutant and wild-type APP695 were purified employing the same methods.  Samples 
were lysed, and then purified through the use of nickel beads, dialysis, a heparin column, and a 
size exclusion column (figure 6).  Prior to lysis, RGB cells containing expressed mutant and wild-
type APP695 were collected from expression cultures by centrifugation at 6000 RPM at 4oC for 




Cell Lysis.  RGB Cells containing expressed mutant and wild-type APP695 protein were 
lysed to release protein.  A 20mM Tris pH 6.8, 100mM NaCl, 5mM EDTA, 0.1 mg/mL lysozyme 















lysis buffer with Sigma Fast Protease Inhibitor was used for the cell lysis, and all cell lysis steps 
were completed on ice to prevent protein degradation.  The RGB cells were first resuspended in 
the lysis buffer and then transferred to a tissue homogenizer.  After homogenization, samples 
were centrifuged at 5,000xg at 4oC for 1 hour.  The pellet was discarded and the supernatant 
was collected.  Two Fast Protease Inhibitor tablets (Sigma-Aldrich, St. Louis, MO) were added to 
the supernatant.   
IMAC Beads.  The protein-containing-supernatant collected during cell lysis step was 
then applied to IMAC beads (Roche Diagnostics, Indianapolis, IN).  IMAC beads contain nickel 
ions, which purify by binding the His-tag attached to mutant and wild-type APP695.  The IMAC 
beads were first equilibrated using an equilibration buffer of 20 mM Tris pH 7.4, 100 mM NaCl, 
and 5 mM EDTA.  The protein sample was then added to the IMAC beads and placed at 4oC for 
4 hours with gentle rocking.  Next, the IMAC bead-protein mixture was centrifuged at 3,000xg 
at 4oC for 10 minutes.  The supernatant was removed and the pellet resuspended in 
equilibration buffer and transferred to a 10 mL centrifuge column.  After the flow through was 
collected, a wash buffer of 20 mM Tris pH 7.4, 250 mM NaCl, 2.5 mM EDTA, a 2 mM imidazole 
was added.  The wash was collected, the columns were closed, and an elution buffer of 20 mM 
Tris pH 7.4, 100 mM NaCl, 5 mM EDTA, and 100 mM imidazole was added. The beads were 
resuspended and placed at 4oC for 20 minutes with gentle rocking.  Finally, the columns were 
opened and the elution containing mutant or wild-type APP695 was collected. 
Dialysis.  Following the IMAC Beads step, the collected elution contained mutant or 
wild-type APP, other proteins, 20 mM Tris pH 7.4, 100 mM NaCl, 5 mM EDTA, and 100 mM 
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imidazole.  The purpose of the dialysis step is to remove the imidazole from the sample.  First, 
5L of a 20 mM Tris pH 7.4, 100mM NaCl, and 5 mM EDTA buffer was prepared.  The sample was 
added to a dialysis bag of MWCO 6-8,000.  The sample-containing dialysis bag was placed into 
the 5 L of buffer for 1 hour.  The dialysis bag was then removed, and the sample was collected 
in a 50 mL conical tube. 
Heparin Column.  Following dialysis, a heparin column was used to further purify 
mutant and wild-type APP695 from solution.  First, the heparin column was cleaned by running 
water, 10 column volumes of 2M NaCl, 10 column volumes of 200 mM NaOH, 20 column 
volumes of 20 M tris pH 8, 10 column volumes of 70% ethanol, and 10 column volumes of 20% 
ethanol 50 mM sodium acetate through it.  The column was then equilibrated with 10 column 
volumes of 20 mM tris pH 7.4, 2.5 mM EDTA.  Next, the sample was loaded onto the column, 
and the flow through was collected.  The column was eluted by fraction collection and 
increasing the concentration of NaCl.  The 1st fraction was collected using 50 mL of 20 mM tris 
pH 7.4, 2.5 mM EDTA, and 0 mM NaCl.  The 2nd fraction was collected using 50 mL of 20mM tris 
pH 7.4, 2.5 mM EDTA, and 100 mM NaCl.  The 3rd, 4th and 5th fractions were collected in similar 
fashion, using 20 mM tris pH 7.4, 2.5 mM EDTA, and 300, 400, or 500 mM NaCl.  The fraction 
containing mutant or wild-type APP695 was determined using a gel and western blot. 
Size Exclusion Column.  The final purification step for mutant and wild-type APP695 is 
size exclusion chromatography.  The heparin column fraction containing mutant or wild-type 
APP695 was run through the sizing column.  Fractions were collected and a gel and western 
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blot was used to determine which fraction contained the target protein.  Samples were used to 
conduct AlphaLISA cleavage assays (PerkinElmer, Waltham, MA). 
VI.  Chinese Hamster Ovary (CHO) Cell Culture 
 Wild-type CHO cells were used for these experiments as they should not express 
endogenous APP, which would cause interference.  Cells were maintained at 37oC in 5% CO2 in 
F-12K media (ATTC, Manassas, VA) supplemented with 10% fetal bovine serum, penicillin, and 
streptomycin in 10 cm tissue culture dishes.  Media was changed every 2 days, and cells were 
split every 3 days or when confluence reached 70-90%. 
VII. Human Embryonic Kidney (HEK) Cell Culture 
 Wild-type HEK cells were 37oC in 5% CO2 in DMEM media (Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum, penicillin, and streptomycin in 10 cm tissue culture 
dishes.  Media was changed every 2 days, and cells were split every 3 days or when confluence 
reached 70-90%. 
VIII. Transfection 
 Wild-type CHO or HEK cells were each transfected with three pcDNA3 plasmids.  The 
first plasmid contains the LacZ gene, and is used for measuring transformation efficiency.  The 
second plasmid contains BACE1, the proteolytic enzyme that cleaves APP at the β-site.  The 
third plasmid contains wild-type or a mutant APP695.  Cells were first transferred from 10 cm 
tissue culture dishes to 24 or 6-well plates.  For LacZ, BACE1, and ADAM10 cleavage assays, 24-
well plates were used.  For western blotting, 6-well plates were used.  Cells were grown to 70-
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90% confluence in 10 cm tissue culture dishes at 37oC in 5% CO2.  The media was removed, and 
3 mL of 0.25% trypsin solution (Corning, Manassas, VA) was added to each tissue culture dish.  
The cells were then incubated at 37oC in 5% CO2 for 10 minutes, then transferred to 15 mL 
conical tubes and centrifuged at 1,500 RPM for 5 minutes at room temperature.  The trypsin 
was then removed, and the cells were resuspended in 4 mL of F-12K media.  For plating on 24-
well plates, 1 mL of resuspended cells was added to 5 mL of F-12K media, and 500 µL of this 
mixture were added to each well in a 24-well plate.  For plating on 6-well plates, 1 mL of 
resuspended cells was added to 12 mL of F-12K media (CHO cells) or DMEM (HEK cells), and 2 
mL of this mixture were added to each well in a 6-well plate.  24 and 6-well plates were 
incubated at 37oC in 5% CO2 until cell confluence reached 70-90%.  Cells were then transfected 
with pcDNA3 plasmids containing LacZ, BACE1, and wild-type or mutant APP695.  The media 
was removed from each well, and 250 µL of fresh media was added to each well in the 24-well 
plate.  One mL of fresh media was added to each well in the 6-well plate.  Five µg of each 
plasmid was added per well, along with 3.5 µL of Lipofectamine per well.  Transfected cells 
were then incubated at 37oC in 5% CO2.  After 4 hours, the media was discarded, and fresh 
media was added (250 µL for 24-well plates; 1 mL for 6-well plates).  Plates were then 
incubated overnight at 37oC in 5% CO2. 
IX. Lysis 
 After transfection and overnight incubation, the media and cell lysis were collected.  The 
media was removed from the cells and transferred to a fresh plate.  1 mL of trypsin was added 
to each well containing transfected cells.  Plates were then incubated at 37oC in 5% CO2 for 5 
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minutes.  The removed media was then place back to its corresponding wells, and the media, 
cell; trypsin mix was moved to 1.5 mL microcentrifuge tubes.  The tubes were spun at 2,000 x g 
for 10 minutes at 4oC.  The supernatant was transferred to new 1.5 mL tubes and protease 
inhibitors were added.  The pellet was resuspended in AlphaLISA HiBlock Buffer with protease 
inhibitors if LacZ and AlphaLISA assays were to be performed.  For western blots, the pellet was 
resuspended in RIPA buffer with protease inhibitors.  Because LacZ and AlphaLISA assays use a 
different lysis buffer than western blot, a single transfection can result in either LacZ and 
AlphaLISA assays or a western blot.  Separate transfections were done for assays and western 
blots. 
X. Western Blot 
 Western blot was used to verify the presence of wild-type or mutant APP695 in cell 
lysate.  CHO or HEK cells grown in 6 well plates were transfected and lysed.  The lysate was then 
sonicated for three 5 second pulses at amplitude of 80 nm to degrade DNA.  The protein 
concentration for each sample was determined through a coomassie assay, and 25-50 µg of 
protein in each sample were added to lanes in a Novex NuPage 4-12% Bis-Tris (Life 
Technologies, Grand Island, NY) and ran at 200V for 55 minutes in MOPS Buffer.  Gels were 
removed and washed 3 times in water, 10 minutes each wash.  GelCode Blue (Life 
Technologies, Grand Island, NY) was added to the gel for 1 hour, followed by water for 30 
minutes.  Protein was then transferred to a nitrocellulose membrane.  5% milk in TBST was used 
for blocking.  Primary antibodies used were 3E9, 2B3, anti-sAPPβ, and anti-BACE.  Secondary 
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antibody was anti-mouse for 3E9 and 2B3; anti-rabbit for anti-sAPPβ and anti-BACE.  Mutant or 
wild-type APP695 was detected using ECL detection kit (Thermo Fisher Scientific, Carsbad, CA). 
XI. LacZ Assay 
 LacZ assay was used to determine the effectiveness of cell transfections.  Fifty µL of LacZ 
buffer was added to 50 µL of cell lysate in a LacZ assay plate.  Plates were read at 420 nm every 
30 minutes for 3 hours. 
XII. BACE and ADAM10 AlphaLISA Cleavage Assay 
 Cell lysate, cell media, and purified mutant or wild-type APP695 were used in AlphaLISA 
assays.  Purified mutant or wild-type APP695 was first added to a well in a 365-well plate with 
acceptor beads and antibody.  BACE or ADAM10 was then added and samples were incubated 
at room temperature for 60 minutes.  Donor beads were added and samples were incubated at 
room temperature for 30 minutes in darkness.  The beads were excited at 530nm, 1O2 produced 
upon binding of the beads in proximal location, and the plates were read at 680 nm. 
Results 
I.  Computer Modeling  
Mapping results suggest that the N585Y mutation could affect the binding site of APP 
and BACE1 as N585 is located in the region where BACE interacts with APP (figure 7).  Other 
mutations are located far from the binding site of BACE1 to APP, but could still cause 
conformational changes that affect BACE1 cleavage.  Not affecting BACE1 cleavage does not 
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mean the mutation does not affect APP proteolysis.  It could be possible that these mutations 




Figure 7.   Model showing the domains of APP and known ectodomain mutations involved 
in this study.  The E1 domain is shown in dark blue.  The E2 domain is shown in green.  The 
Aβ region is shown in red.  The acidic domain and JMK region are shown in cyan.  The three 
mutations N585Y, E191G, and H147N are shown in yellow.  The N585Y mutation is located 
near the β-cleavage site and hence likely to affect BACE1 interaction with APP.  The other 
mutations may affect APP conformation and shape, which could also affect interaction 
with BACE1 or alter cellular trafficking of APP. 
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II. Protein Purification 
 Mutant and wild-type APP695 were purified for BACE assays that would measure 
protein sensitivity to BACE cleavage.  Mutant or wild-type APP695 plasmids were transformed 
into RGB cells and expression was induced.  RGB cells were lysed, and the lysate was applied to 
IMAC beads, a heparin column, and a sizing column.  A gel shows the fully purified H147N and 





III. CHO Cells 
To determine the effect of mutations on APP cleavage, mutant and wild-type APP was 
transfected into wild-type CHO cells.  Cells were lysed after 48 hour incubation at 37oC in 5% 
CO2, and lysis was analyzed using a 4-12% bis-tris gel and western blot.  A primary antibody for 
GAPDH was used to show protein concentration was equal in each well (figure 9).  A primary 
antibody for BACE was used to show the presence of BACE in cells containing BACE pcDNA3 
plasmid (figure 9).  Primary antibodies for sAPPα and sAPPβ were used to detect the presence 
of APP cleavage products (figure 9) and primary antibody 3E9 for APP and APP cleavage 
products was used to detect presence of APP.  ELISA assays were used to measure sAPPα and 
sAPPβ levels in media and cell lysate and the percent change in sAPPβ and sAPPα levels were 




Figure 8.   Gel of purified and partially purified mutant APP695.  The E191G and H147N 
have been fully purified and are ready for BACE assay.  The N585Y has only been partially 
purified.  The N585Y lysate was applied to the IMAC beads and the supernatant (sup), 
wash, flowthrough (FT), and elution (N585Y) were collected.  The N585Y elution will next 






Figure 9.  Western Blot for BACE, sAPPα, sAPPβ, and GAPDH in transfected CHO cells.  BACE 
was only detected in samples transfected with the BACE pcDNA3 plasmid. Only cells 
transfected with mutant APP without BACE show sAPPα.  The N585Y mutant shows a 
stronger sAPPα band than E191G.  Only cells transfected with mutant APP and BACE show 
sAPPβ.  The blot was cropped to exclude a nonspecific band below.  The N585Y mutant 
shows a stronger sAPPβ band than E191G. 
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Figure 10.  Percent change in the media after BACE transfection.  The E191G mutant 





IV. HEK293T Cells 
 To determine the effect of mutations on APP cleavage, mutant and wild-type APP was 
transfected into wild-type CHO cells.  Cells were lysed after 24 hour incubation at 37oC in 5% 
CO2, and lysis was analyzed using a 4-12% bis-tris gel and western blot.  Primary antibody 3E9 
was used to detect the presence of mutant or wild-type APP mutants (figure 12).  APP and APP 























Percent Change in Lysate
sAPPβ
sAPPα
Figure 11.  Percent change in the media of sAPPβ and sAPPα levels after BACE transfection.  
The N585Y displayed a greater change in sAPPβ levels. 
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APP.  Following western blot, AlphaLISA assay was used to measure levels of Aβ and sAPPα.  For 
this experiment we also used the H147N mutation along with the other two mutations 
described above.  Results showed a significant decrease in the H147N levels of Aβ, suggesting 
this mutation could be protective against LOAD while the Aβ levels for N585Y and E191G 
mutants were unaffected (figure 13).  The N585Y mutation showed a significant decrease in 
sAPPα levels, while the H147N and E191G mutations were unaffected (figure 14) suggesting 
that it has a greater propensity to be pathogenic.  Using the data obtained from sAPPα and Aβ 
measurements, the ratio of sAPPα to Aβ was calculated (figure 15).  The ratio of sAPPα/Aβ was 
decreased in cells transfected with N585Y.  Cells transfected with E191G did not show an 




Figure 12.  Western blot for APP in transfected HEK cells.  No APP was detected in 
nontransfected samples and not a significant amount of E191G possibly due to proteolysis. 


















Figure 13.  Aβ levels from transfected HEK cell lysate by AlphaLISA assay.  H147N shows 



























Figure 14.  sAPPα levels from transfected HEK cells by AlphaLISA assay.  The















  Our results have shown that only the N585Y mutation can result in APP proteolysis 
leading to decreased trophic sAPPα and increased anti-trophic sAPPβ.  The N585Y is located 
near the binding site of APP and BACE1.  It is possible that the N585Y mutation alters the 
binding site of this complex, increasing the affinity between BACE1 and APP, resulting in 


























sAPPα/Aβ in HEK Cells
?
Figure 15.  The log of the ratio of sAPPα to Aβ levels in HEK cell media normalized to wild-
type ratio.  The ratio of sAPPα/Aβ was decreased in the cells transfected with N585Y and 
increased in cells transfected with H147N.  Cells transfected with E191G showed only slight 
variation from wild-type. 
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individuals with the N585Y mutation.  This increase in anti-trophic factor production in our 
experiments suggests that individuals with the N585Y mutation are at greater risk of LOAD. 
 The E191G mutation is located distal from the APP-BACE1 binding site in the acidic 
region of APP.  While this mutation would not alter the binding site, it is possible that these 
mutations could change the conformation of the APP protein, affecting either BACE1 or 
ADAM10 binding leading to altered APP proteolysis.  Results for the E191G mutation show that 
sAPPβ levels in the media of CHO cells showed a greater increase in BACE activity than the 
N585Y mutation (figure 10).  However, the sAPPβ levels in cell lysate showed that the N585Y 
mutation produce greater amounts of anti-trophic peptides (figure 11) suggesting that the 
E191G mutation allows for better trafficking to and excretion through the plasma membrane. 
 In contrast, the H147N mutation in the CuBD has been previously reported to increase 
sAPPα, and in our experiments we show that it would confer a protective effect against LOAD. 
 BACE1 cleavage of APP results in the formation of sAPPβ.  During the transition from 
APP to sAPPβ, a structural change occurs.  It is possible that APP ectodomain mutations alter 
the structure of APP and affect APP proteolysis.  For example, a mutation that decreases the 
stability of sAPPβ, while not affecting the stability of APP, would result in increased BACE1 
cleavage.  A mutation that increases the stability of sAPPβ, while not affecting the stability of 
APP, would result in decreased BACE1 cleavage. 
 Computer modeling (figure 7) has allowed us to form a hypothesis about some of the 
effects of LOAD mutations.  Further investigation of these mutations will be necessary to 
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determine the accuracy of those predictions.  Mutant APP695 will be transfected into CHO cells, 
and cleavage products will be measured and compared to cleavage products from wild-type 
APP695.  Purified mutant APP695 will be tested using fluorescence and AlphaLISA assays. 
 Mutant and wild-type APP was transfected into CHO cells.  Western blot results show 
that GAPDH levels appeared similar in all samples, indicating that the total protein levels in 
each well were equal.  BACE was only detected only in samples where the BACE pcDNA3 
plasmid had been transfected, showing that BACE transfections were successful and that BACE 
was not present in cells not transfected with BACE pcDNA3 plasmid.  Western blots for sAPPα 
and sAPPβ showed sAPPα present only in mutant samples not transfected with BACE. 
Therefore, nontransfected CHO cells primarily cleave transfected mutant APP at the α-site.  
However in CHO cells also transfected with BACE, sAPPβ was detected in western blots rather 
than sAPPα.  When CHO cells were transfected with BACE pcDNA3 plasmid, mutant APP was 
cleaved primarily at the β-site.  Western blots for sAPPα and sAPPβ also showed that no 
cleavage products were detected for wild-type APP transfections, indicating an issue with the 
wild-type APP pcDNA3 plasmid.  The wild-type plasmid is a necessary part of the experiment, 
and before further transfections can occur the wild-type APP pcDNA3 plasmid reagent should 
be quantified using nanodrop technology and possibly sequenced.  If further issues occur, fresh 
wild-type APP pcDNA3 should be synthesized before continuing the project.  Western blots 
using the 3E9 antibody for APP showed APP present in all samples, including those where APP 
was not transfected.  This could mean that CHO cells express endogenous APP or that the 
pcDNA3 plasmid and BACE pcDNA3 contain APP.  If CHO cells do express endogenous APP, a 
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different cell type would be better for our experiments.  DNA sequencing should be used to 
determine if suspect plasmids contain APP. 
 CHO cell media and lysate from transfections were analyzed by ELISA assay.  The first 
measurements were taken using a single set of samples from media collected after 24 and 48 
hours of incubation and cells lysed after 48 hours of incubation.  Measurements matched 
western blot results showing that sAPPα was only detected in cells transfected with only 
mutant APP.  When BACE was present, sAPPα levels were low.  Also matching western blot 
results, the N585Y mutant showed higher sAPPα levels than the E191G mutant.  According to 
these results, the N585Y mutation may have a higher affinity for α secretase than the E191G 
mutation.  When BACE was added, sAPPα levels dropped steeply for both mutants, with the 
E191G displaying higher sAPPα levels than the N585Y.  In the future, the assay will have to be 
done with more samples to obtain standard deviations. 
 The ELISA assay measurements were taken using 3 sets of samples that were pooled 
together.  Normally, it would be better to make measurements by measuring the 3 samples 
individually and calculating the average and standard deviation.  However, we were short of 
reagents and opted to pool the samples together to obtain results that would be more accurate 
that measuring one sample alone.  Results matched what we discovered from the western blots 
and first ELISA assay. 
 The third ELISA assay measurements were taken in the same way as the second 
measurements.  Cells transfected with mutant APP and BACE showed high levels of sAPPβ 
compared to cells transfected with just mutant APP, matching western blot results.  The N585Y 
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mutation produced greater levels of sAPPβ than the E191G mutation, indicating that it may 
have more affinity for BACE and could lead to increased pro-AD fragments.   
 Western blots of HEK293T cells showed that no endogenous APP was being expressed 
unlike CHO cells where some level of APP expression was observed.  Hence, use of HEK293T 
cells for our experiments is better than CHO cells. 
 The AlphaLISA results obtained from HEK cell transfections showed that the H147N 
mutation displayed a decrease in Aβ levels and an increase in sAPPα/Aβ ratio, and the N585Y 
mutation displayed a decrease in sAPPα levels and a decrease in sAPPα/Aβ ratio (figure 16).  
The H147N mutation could possibly be protective against AD by lowering levels of Aβ in the 
brain.  Identification of this mutation in human APP has not been reported.  The data suggests 
that the H147 residue may play an important role in dictating a protective conformation of APP.  
The H147N mutation is located far from the Aβ region and β-site of APP.  In order to affect Aβ 
production, the H147N mutant might disrupt the shape of APP, altering APP ability to interact 
with β-secretase.  Another possibility is that the H147N mutation affects the copper binding 
domain, which is located nearby.  The activity of the copper binding domain may play an 






 The N585Y mutation showed a decrease in sAPPα levels and an increase in sAPPβ in 
both CHO and HEK cells and decreased sAPPα/Aβ ratio, hence this mutation would increase the 
risk of onset of LOAD.  Unlike the H147N mutation, which we show decreased Aβ and increased 
sAPPα/Aβ ratio and would be protective against LOAD, and the E191G mutation, which appears 
to be less harmful, the N585Y mutation is located near the α and β cleavage sites.  The N585Y 
mutation appears to alter the ability of APP to interact with BACE or ADAM10, thus leading to a 
decrease in sAPPα levels.  In the brain, lower levels of sAPPα would lead to a decreased trophic 
Figure 16.  Table summarizing the results in HEK cells.  The N585Y showed decreased levels 
of sAPPα and decreased ratio of sAPPα/Aβ.  The E191G slightly increased the ratio of 
sAPPα/Aβ.  Finally, the H147N decreased Aβ levels and increased the ratio of sAPPα/Aβ. 
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effect on neurons.  With less trophic factors, neural cells have decreased lifespan leading to 
quicker neurodegeneration.  Individuals that have the N585Y mutation, that could be 
determined by a blood based genetic analysis, should make necessary lifestyle changes, such as 
using the metabolic enhancement for neurodegenerative diseases (MEND) approach (42), to 
delay AD, as our data suggest these subjects are at higher risk. 
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